AIM ImmunoTech (AIM) announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions for Treating LONG COVID,” covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen for use in the treatment of Long COVID.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech Updates Certificate of Incorporation
- AIM ImmunoTech Presents at Maxim Growth Summit 2025
- AIM ImmunoTech presents Phase 1a trial data for faridoxorubicin
- AIM ImmunoTech secures patent in Japan through 2039 for therapy using Ampligen
- AIM ImmunoTech announces publication on effect of Ampligen